Abstracts

669 DURABLE RESPONSES WITH TRIPLE BLOCKADE OF THE DNAM-1 AXIS WITH COM701 + BMS-986207 + NIVOLUMAB IN PATIENTS WITH PLATINUM RESISTANT OVARIAN CANCER

1Stephanie Gallard, 2Manish Sharma, 3Daniel Vaena, 4Oladapo Yeku, 5Ilan Ben-Moshe, 6Ecaterina Dumbrava, 7Kyriakos P Papadopoulos, 8Amita Patnaik, 9Ryan Sullivan, 10Benjamin Izar, 11Ilan Barbiro, 12Adeboye Adewoye, 13John Moroney, 14Johns Hopkins, MD, USA; 15START Midwest, Chicago, IL, USA; 16West Cancer Center and Research Institute., Memphis, TN, USA; 17Massachusetts General Hospital, Boston, MA, USA; 18START San Antonio, San Antonio, TX, USA; 19The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 20START Cancer Center, San Antonio, TX, USA; 21Columbia University, New York, NY, USA; 22Compugen, Toulouse, France; 23Compugen Ltd, Holon, Israel; 24Compugen USA Inc., San Francisco, CA, USA; 25University of Chicago, Chicago, IL, USA

Background Treatment options for patients with platinum resistant ovarian cancer [PROC] are limited. Immune checkpoint inhibitors (ICI) have limited activity in PROC, therefore clinical studies evaluating novel therapies are urgently needed. We have previously reported durable and a complete response with COM701 +/- BMS986207 + nivolumab. COM701 is a novel, 1st-class ICI binding to PVRIG, that leads to activation of T-cells. BMS-986207 is an ICI of TIGIT. We report longer term follow-up showing continued durable responses in patients with PROC treated with a triple immunotherapy combination blocking the DNAM-1 axis with COM701 + BMS-986207 + nivolumab (NCT04570839).

Methods We enrolled 20 patients with PROC treated with COM701 20 mg/kg + BMS-968207 480 mg + nivolumab 480 mg IV Q4W. Primary objectives were safety/tolerability; secondary objective of preliminary antitumor activity. Key inclusion criteria: Age ≥ 18 yrs, histologically confirmed advanced malignancies and exhausted all available standard treatments. Key exclusion criteria: prior receipt of any inhibitor of PVRIG, TIGIT, or PD-(L)-1. Investigator assessed responses per RECIST v1.1, safety per CTCAE v5.0.

Results No new safety signals are reported. The combination is well tolerated. There were 4/20 (20%) patients with confirmed PR and 5 pts with SD with a DCR [CR+PR+SD] 9/20 [45%], no CRs. Median [med] age 61yr, med number of prior lines of therapy - 4 [range 1–10]. Histology of patients with PR – high grade serous adenocarcinoma [3 pts], clear cell histology [1 pt]. Three pts continue study treatment at 449, 428 and 477 days, 1 pt with high grade serous adenocarcinoma was on study treatment for 222 days.

Conclusions Continued durable confirmed partial responses by blocking the DNAM-1 axis with the combination of COM701 + BMS-986207 + nivolumab in pts with heavily pre-treated PROC. Additional translational data will be presented at the conference. Data extract 06/09/2023.

Acknowledgements We thank the patients for participating in this clinical trial and their families, the investigators and their staff at the clinical trial sites; Study Sponsor Compugen Ltd in collaboration with Bristol Myers Squibb; Danae Hudson, Amanda Harp, Compugen USA Inc for clinical operations oversight of the study.

Trial Registration NCT04570839.

REFERENCE

Ethics Approval The study obtained ethics approval as below: